The Latest Cardiac and Vascular News
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare’s portfolio of AI-enabled devices AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency Planned acquisition supports GE HealthCare’s precision care strategy to address inefficiencies and […]
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024.
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 […]
Dr. Mettler comes to Le Bonheur from Johns Hopkins Children’s Center
MEMPHIS, Tenn., July 17, 2024 /PRNewswire/ — Le Bonheur Children’s Hospital has named Bret A. Mettler, MD, its new Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute at Le Bonheur and the University of Tennessee Health Science Center. Dr. Mettler will also hold The Susan and Alan Graf Endowed Chair in Pediatric Heart Surgery at Le Bonheur.
He comes to Le Bonheur and UT Health Science Center from Johns Hopkins Children’s Center, where he serves as Director of Pediatric Cardiac Surgery and Co-Director of the Blalock-Taussig-Thomas Pediatric and Congenital Heart Center.
Before his time at Johns Hopkins, Dr. Mettler served as the Director of Cardiac Transplantation and Mechanical Circulatory Support at Vanderbilt University Medical Center in Nashville.
“I am excited for Dr. Mettler to join our talented and dedicated team at Le Bonheur and UT Health Science Center,” said Le Bonheur President Trey Eubanks, MD, FACS. “Bret brings a wealth of knowledge and experience which will allow us to continue our Heart Institute’s mission of providing excellent care for children with complex heart conditions.”
Dr. Mettler specializes in the surgical repair of complex congenital heart disease, heart transplantation and mechanical circulatory support. His research interests include insights into complex congenital heart defects and the development of an artificial pulmonary valve using stem cells.
“Le Bonheur is committed to excellence and providing outstanding care for patients,” said Dr. Mettler. “The Heart Institute has a world-class faculty built by Drs. (Chris) Knott-Craig and (Jeffrey A.) Towbin, and I am pleased to be part of building on that foundation. Le Bonheur really shines for its care for children in an environment built just for them. I am excited about our continued vision for growth and service to the community.”
Le Bonheur Children’s Announces Dr. Brett Mettler, page two of two
Dr. Mettler assumes the chief of Pediatric Cardiac Surgery and executive co-director of the Heart Institute roles from Christopher Knott-Craig, MD, who last year announced he plans to step down as chief and executive co-director of the Heart Institute. Dr. Knott-Craig, along with Dr. Jeffrey A. Towbin, the executive co-director of the Heart Institute and chief of Pediatric Heart Failure and medical director of Cardiomyopathy, Heart Failure and Heart Transplant Services, have been responsible for leading Le Bonheur’s Heart Institute to become a Top 10 program in U.S. News & World Report. They have built the reputation of Le Bonheur’s Heart Institute as an elite surgical and medical program and developed the new 31-bed Cardiovascular Intensive Care Unit. Le Bonheur will honor Knott-Craig and his tenure later this summer.
“I want to thank the medical, surgical and nursing members of the Heart Institute for their very substantial role in helping to recruit Dr. Mettler and for their long-term commitment to excellence and the special care given to their patients,” said Dr. Towbin, who also serves as chief of Cardiology at Le Bonheur and St. Jude Children’s Research Hospital and tenured professor, Department of Pediatrics, Pediatric Cardiology at UT Health Science Center. “I am excited for Le Bonheur’s future and for the innovation that Dr. Mettler brings to Memphis. He is a wonderful addition to our outstanding team.”
Dr. Mettler is a native of South Dakota. He, along with his wife Kelly and their two daughters, will move to Memphis later this year.
About Le Bonheur Children’s Le Bonheur Children’s, based in Memphis, Tenn., provides expert care for children in more than 45 pediatric subspecialties, encompassing robust community programs, a pediatric research institute and regional outpatient centers in Jackson, Tenn., Tupelo, Miss., and Jonesboro, Ark. Le Bonheur also features a 255-bed hospital in Memphis and a 21-bed satellite hospital within Jackson-Madison County General Hospital in Jackson, Tenn. As the primary pediatric teaching affiliate for the University of Tennessee Health Science Center, Le Bonheur trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur has been named a U.S. News & World Report Best Children’s Hospital for 13 consecutive years and is a Magnet-designated facility, the ultimate credential for high-quality patient care and nursing excellence.
For more information, please call (901) 287-6030 or visit lebonheur.org. Connect with us at facebook.com/lebonheurchildrens, x.com/lebonheurchild on Instagram at lebonheurchildrens.
About University of Tennessee Health Science CenterThe mission of the University of Tennessee Health Science Center is transforming lives through collaborative and inclusive education, research, scholarship, clinical care, and public service. With six colleges – Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy – at its main campus in Memphis, in addition to educational and clinical campuses at major hospitals in Memphis, Knoxville, Chattanooga, and Nashville, and sites across the state, UT Health Science Center strives to fulfill its vision: Healthy Tennesseans. Thriving Communities. For more information, visit www.uthsc.edu. You can find the University of Tennessee Health Science Center on Facebook, Instagram, LinkedIn, X, and YouTube.
CONTACT: David Henson(423) 304-9400 [email protected]
Ariss Arena (901) 283-5584 [email protected]
SOURCE Le Bonheur Children’s Hospital
July 17, 2024 Patient monitoring platform to deliver tools and time to help patients across 40+ care sites Amsterdam, the Netherlands, and Cincinnati, Ohio – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and Bon Secours Mercy Health (BSMH), one of the nation’s largest Catholic health systems, today announced a multi-year strategic collaboration for patient monitoring. Putting BSMH clinicians in control, the collaboration will reduce the digital burden on staff and give them more time to spend with patients. The partnership provides access to the latest Philips monitoring innovations, including a scalable patient monitoring platform that integrates patient data and provides vital insights. It will standardize patient monitoring for BSMH’s 49 hospitals, reducing costs through a predictable payment model and enabling further reinvestment in innovation. “This collaboration is part of our commitment to drive improved healthcare quality while reducing costs and addressing healthcare issues facing entire communities,” said Jodi Pahl, Chief Nursing Officer for workforce experience and nursing outcomes, Bon Secours Mercy Health. “This 10-year journey will bring innovations that will transform care delivery.” BSMH provides patients care more than 11 million times annually through its network of more than 1,200 care sites, 60,000 associates and 49 hospitals serving communities in Florida, Kentucky, Maryland, New York, Ohio, South Carolina and Virginia, as well as Ireland. “With implementation occurring over the next three years, followed by seven years of maintenance and updates, we’re positioned to be at the leading edge of technology,” said Pahl. “This uplifts our Mission to improve the health and well-being of our communities and supports our commitments to innovation and stewardship.” Julia Strandberg, Chief Business Leader, Connected Care at Philips said: “This partnership is a testament to BSMH’s focus on strong clinical engagement and our combined commitment to improving the patient and staff experience. As BSMH’s clinical technology partner, we’re leaning in to understand their needs and apply innovative technologies that can improve patient outcomes. BSMH is committed to bringing quality care to more people by eliminating time-consuming data roadblocks for their staff.” For further information, please contact: Silvie CasanovaPhilips North America Tel: +1 781 879-0692 Email: silvie.casanova@philips.com Mark GrovesPhilips External RelationsTel: +31 631 639 916Email: mark.groves@philips.com Emma SwannBon Secours Mercy HealthTel: +1 804 837-0413Email: Emma_swann@bshsi.org About Bon Secours Mercy HealthBon Secours Mercy Health (BSMH) is one of the 20 largest health systems in the United States and the fifth-largest Catholic health system in the country. The ministry’s quality, compassionate care is provided by more than 60,000 associates serving communities in Florida, Kentucky, Maryland, New York, Ohio, South Carolina, and Virginia, as well as throughout Ireland. Bon Secours Mercy Health provides care for patients more than 11 million times annually through its network of more than 1,200 care sites, which includes 49 hospitals. In 2023, BSMH provided more than $600 million dollars in community investments across five states, ensuring that cost is not a barrier to health care for our patients in need. In addition to charity care, BSMH invests in programs that address chronic illness, affordable housing, access to healthy food, education and wellness programs, transportation, workforce development and other social determinants of health that directly affect the communities we serve. The Mission of Bon Secours Mercy Health is to extend the compassionate ministry of Jesus by improving the health and well-being of its communities and bring good help to those in need, especially people who are poor, dying and underserved. For more information, visit https://bsmhealth.org/. About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
Doctor monitoring patient health
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st. To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. Starting on July 17th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: https://app.saytechnologies.com/amarin-2024-q2. This Q&A platform will remain open until 24 hours prior to the start of the earnings call. Shareholders can email support@saytechnologies.com for any support inquiries. Conference Call and Webcast Information: Access to the live call: Go to the investor relations section of the Company’s website at www.amarincorp.com Dial in within the United States: 888-506-0062International dial in: 973-528-0011Access Code: 409616Access to replay: Dial in within the United States: 877-481-4010 International dial in: 919-882-2331 Access Code: 50766A replay of the call will also be available through the Company’s website shortly after the call. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk. Availability of Other Information About Amarin Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information Investor & Media Inquiries: Mark Marmur Amarin Corporation plc PR@amarincorp.comInvestor.relations@amarincorp.com
BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com. LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.
July 16, 2024 06:30 AM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth […]
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website. About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. Investor Contact: Marissa BychGilmartin Group LLCIR@inarimedical.com
July 16, 2024 09:00 AM Eastern Daylight Time BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has raised a $260 million Series B financing led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management […]
